Option chain shows key data for Takeda Pharmaceutical Co's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Takeda Pharmaceutical Co.

Takeda Pharmaceutical Co (OTC:TKPHF) Stock, Option Chain

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Biotech

News

Health Care

Contracts

Small Cap

Movers

Trading Ideas

General

TBPH

TKPHF

In its Q1 earnings release, Takeda Pharmaceutical Co Ltd (NYSE: TAK) said it agreed to discontinue further development of TAK-954 for post-operative gastrointestinal dysfunction and the parties&#39; collaboration agreement with Theravance Biopharma Inc 

Takeda Moves Out From Licensing Agreement With Theravance Biopharma

Earnings

Guidance

Pre-Market Outlook

Takeda Pharmaceutical Co Ltd&#39;s (NYSE: TAK) FY22 net profit rose 37.8% to ¥317.02 billion, mainly due to solid growth in its 

Takeda&#39;s FY22 Net Profit Jumps 38%, But Expects Lower FY23 Revenues

Government

Media


	The Pan American Health Organization (PAHO) is reportedly in early talks with Takeda Pharmaceutical Co Ltd (NYSE: TAK) regarding the potential orders of its dengue vaccine, TAK-003.


United Nations&#39; Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review

TAKEDA PHARM CO LTD ORD by Takeda Pharmaceutical Co., Ltd.

Takeda Pharmaceutical Co Ltd

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Hutchmed (HCM) announced that it will receive a milestone payment following the pricing approval and launch of Fruzaqla 1mg/5mg capsules in Japan b...

Hutchmed to receive milestone payment following Takeda launch of Fruzaqla

Takeda Pharmaceutical Co (JP:4502) has released an update. Takeda Pharmaceutical Co has reported strong momentum in its Growth & Launch Products an...

Takeda Shows Strong Growth and Raises Guidance

Keros Therapeutics (KROS) announced an exclusive global development and commercialization license agreement with Takeda (TAK) to advance elritercep...

Keros Therapeutics announces global license agreement with Takeda

Takeda (TAK) announced that it has entered into an exclusive licensing agreement with Keros Therapeutics (KROS) to further develop, manufacture and...

Takeda, Keros Therapeutics enter exclusive elritercept license agreement

Takeda Pharmaceutical: Dividend Yield Is High But Hides Pitfalls Especially For US Investors

Keros Therapeutics: How To Respond To Today's Major Safety Setback And Selloff

Hutchmed (HCM) announced hat it will receive a $10M milestone payment by its partner Takeda (TAK). Takeda received a national reimbursement recomme...

Hutchmed to receive milestone payment from Takeda

Takeda Pharmaceutical Co (JP:4502) has released an update. Takeda Pharmaceutical is advancing its late-stage pipeline with promising treatments acr...

Takeda Eyes Growth with Late-Stage Pipeline

In a report released yesterday, Michael Nedelcovych from TD Cowen maintained a Buy rating on Takeda Pharmaceutical Company (TAK – Research Report)....

Comments

Takeda Pharmaceutical Co

Takeda Pharmaceutical Co (TKPHF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga